Burcon announces publication of Puratein(R) toxicology study



    VANCOUVER, Aug. 20 /CNW/ - Burcon NutraScience Corporation (TSX - BU)
("Burcon" or the "Corporation") announced today the acceptance for publication
of a peer-reviewed manuscript describing a toxicology study of Puratein(R)
canola protein isolate. The toxicology study was originally conducted to
establish the safety of Puratein(R) canola protein isolate in food and
beverage applications and ultimately to support the process of obtaining
Generally Recognized As Safe status ("GRAS status") for Puratein(R) in the
United States. The manuscript, titled "A 13-week sub-chronic dietary toxicity
study of a cruciferin-rich canola protein isolate in rats", has been accepted
for publication in the journal of Food and Chemical Toxicology. Publication of
this study is an important step in the process of obtaining GRAS notification
for Burcon's Puratein(R) canola protein isolate.
    The consumption of canola/rapeseed products in the Western world is
recent and has been limited to the use of the oil for cooking and in salads
and as canola meal in the livestock industry. Burcon's technological advances
have made possible the production of canola protein isolates suitable for
human consumption as ingredients in higher amounts and in a broader range of
foods. Besides their inherent nutritional value and low levels of
anti-nutritional factors, Burcon's protein isolates possess unique functional
properties such as emulsifying and binding characteristics and transparency
when added to beverages. Burcon's two canola protein isolates are rich in
either cruciferin or napin, the major canola protein components.
    The objective of this study was to evaluate the safety of Puratein(R) (a
cruciferin-rich canola protein isolate) when fed as a protein source at
various dietary levels to rats for 13-weeks. Luis Mejia, director of
scientific and regulatory affairs of Archer Daniels Midland Company ("ADM"),
is the primary author of the study. As previously disclosed, the results of
the trial confirmed that Burcon's Puratein(R) canola protein isolate - as
produced using Burcon's patented technology - is safe for it's intended use in
food and beverage applications,
    "With the publication of this study we are another step closer to having
our canola protein isolates GRAS notified," said Johann F. Tergesen, Burcon's
president and C.O.O. "A number of the global food and beverage companies who
have entered into material transfer agreements with Burcon to evaluate our
canola proteins have indicated their desire that Puratein(R) and Supertein(TM)
attain GRAS notification."
    Scientific studies including toxicology studies evaluating the safety of
both Puratein(R) and Supertein(TM) were conducted during fiscal 2008 and based
on those studies, Burcon and ADM prepared a dossier of data that included
scientific information about canola seed, how canola is grown, handled and
processed, Burcon's protein extraction process and finally, the intended uses
of Puratein(R) and Supertein(TM) in foods and beverages. A panel of qualified
experts in the fields of food safety, toxicology, nutritional sciences, food
allergies and pediatric nutrition reviewed the dossier to which the panel also
had input and affirmed unanimously that the proteins are safe for their
intended uses. In October 2008, Burcon's Puratein(R) canola protein isolate
and Supertein(TM) canola protein isolate achieved self-affirmed GRAS status.
    To enhance the acceptance of Puratein(R) canola protein isolate and
Supertein(TM) canola protein isolate with global food and beverage companies,
Burcon and ADM have chosen to pursue GRAS notification for Puratein(R) canola
protein isolate and Supertein(TM) canola protein isolate. GRAS notification is
a voluntary procedure whereby a company informs the U.S. Federal Food and Drug
and Administration ("FDA") of its determination that the use of a substance is
GRAS.
    A substance is GRAS notified when, after reviewing the GRAS notification,
the FDA responds with a no-objection letter if it is satisfied with the
submission.
    After pre-consultation with the FDA, Burcon and ADM concluded that they
would, prior to submitting the GRAS notification, submit the scientific
studies which were incorporated into the GRAS dossier (the toxicology studies)
to peer reviewed journals for publication. The subject of today's announcement
is the publication in the peer-reviewed journal of Food and Chemical
Toxicology of the Puratein(R) canola protein isolate manuscript. Burcon and
ADM have also submitted the toxicology study conducted for Supertein(TM)
canola protein isolate to a peer-reviewed journal for publication. Once the
Supertein(TM) toxicology study is accepted for publication, Burcon and ADM
will proceed to submit the GRAS notification for Puratein(R) and Supertein(TM)
to the FDA.
    Burcon and ADM will submit the GRAS notification using information
contained in the dossier that has been approved by the panel of qualified
experts for the self-affirmation process including the published toxicology
studies. Upon receipt of the notification, the FDA is expected to respond in
accordance with the FDA's established timelines which could take up to 180
days.
    Although Burcon and ADM have determined to pursue GRAS notification to
enhance market acceptance of Burcon's proteins, Puratein(R) canola protein
isolate and Supertein(TM) canola protein isolate are already self-affirmed
GRAS and may be marketed and sold for human consumption in the United States.

    About Burcon NutraScience
    Burcon is a leader in nutrition, health and wellness in the field of
functional, renewable plant proteins. Since 1999, Burcon has developed a
portfolio of composition, application, and process patents originating from
our core protein extraction and purification technology. We are developing the
world's first commercial canola proteins, Puratein(R) and Supertein(TM) with
unique functional and nutritional attributes, and CLARISOY(TM), a
revolutionary soy protein isolate which is 100% soluble and completely
transparent in acidic solutions. Our team of highly specialized scientists and
engineers work from our own research facility to develop and optimize
environmentally sound technologies. To-date, our patent portfolio consists of
86 issued patents in various countries, including 8 issued U.S. patents, and
in excess of 200 additional pending patent applications, 61 of which are U.S.
patent applications.

    
    ON BEHALF OF THE BOARD OF DIRECTORS
    "Johann F. Tergesen"
    Johann F. Tergesen
    

    Burcon NutraScience Corporation is a publicly listed on the Toronto Stock
Exchange under the symbol "BU". For more information on Burcon, visit
www.burcon.ca.

    This press release contains forward-looking statements that involve risks
and uncertainties. These forward-looking statements relate to, among other
things, the Corporation's, plans and timing for the introduction or
enhancement of our products, statements about future market conditions, supply
and demand conditions, and other expectations, intentions and plans contained
in this press release that are not historical fact. Our expectations regarding
the prospect for future success depend upon our ability to develop and sell
products, which we do not produce today and cannot be sold without further
research and development. When used in this press release, the words "goal",
"intend", "believes", "potential", "expected", "anticipates", "will be", and
similar expressions, generally identify forward-looking statements. These
statements reflect our current expectations. They are subject to a number of
risks and uncertainties. In light of the many risks and uncertainties
surrounding the development of a source of protein from canola meal, you
should understand that we cannot assure you that the forward looking
statements contained in this press release will be realized.





For further information:

For further information: Jade Cheng, Chief Financial Officer, Burcon
NutraScience Corporation, (604) 733-0896/(888) 408-7960 toll-free,
jcheng@burcon.ca, www.burcon.ca; AXINO AG, Wolfgang Seybold, Investor
Relations Europe, AXINO AG, KönigstraBe, 26, 70173 Stuttgart, Germany, Tel.
+49-711-25 35 92-40/Fax +49-711-25 35 92-55, wolfgang.seybold@axino.de,
www.burcon.net

Organization Profile

Burcon NutraScience Corporation

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890